公开(公告)号：WO2020069054A1

公开(公告)日：2020-04-02

申请号：PCT/US2019/053049

申请日：2019-09-26

Applicant: TEXAS TECH UNIVERSITY SYSTEM

Inventor： GARG, Himanshu ,  JOSHI, Anjali

IPC: A61K39/00 ,  A61K39/12 ,  A61P29/00 ,  C12N7/02 ,  C12N7/04

Abstract: The present invention includes nucleic acids, proteins, Chikungunya virus (CHIKV) Virus Like Particles (VLP), and methods of making a Chikungunya virus (CHIKV) Virus Like Particles (VLP) comprising: inserting one or more nucleic acids into a lentiviral backbone, wherein the nucleic acid encodes one or more Chikungunya virus (CHIKV) proteins; transfecting the one or more nucleic acids into the lentiviral backbone into a cell line; culturing the transfected cell line under conditions in which the Chikungunya virus (CHIKV) Virus Like Particles (VLP) are released from the cell line; and isolating the Chikungunya virus (CHIKV) Virus Like Particles (VLP) from a culture supernatant.

公开(公告)号：WO2016018664A2

公开(公告)日：2016-02-04

申请号：PCT/US2015/041146

申请日：2015-07-20

Applicant: TEXAS TECH UNIVERSITY SYSTEM ,  GARG, Himanshu ,  JOSHI, Anjali

Inventor： GARG, Himanshu ,  JOSHI, Anjali

IPC: A61K48/00 ,  C12N15/867

CPC classification number: C12N15/86 ,  A61K31/519 ,  A61K38/45 ,  A61K48/0058 ,  A61K48/0091 ,  C07K14/005 ,  C12N9/1211 ,  C12N2740/15043 ,  C12N2740/15052 ,  C12N2740/16022 ,  C12N2740/16043 ,  C12N2830/30 ,  C12Y207/01021

Abstract: A method, system, and apparatus for treating a patient with HIV. A vector can be modified from a thymidine kinase gene. The modified vector is expressed in the presence of tat RNA. The modified vector is then package and delivered to HIV-infected cells. The replication of HIV is inhibited by eliminating infected cells in the presence of Ganciclovir. Modified cells are then selected utilizing transient tat RNA transfection and GFP expression. Vector-modified stem cells are then selected for transplantation back into the patient, thereby producing a normal immune system in the patient when the modified vector remains dormant in the absence of HIV tat.

Abstract translation: 用于治疗HIV患者的方法，系统和设备。 可以从胸苷激酶基因修饰载体。 修饰的载体在tat RNA存在下表达。 然后将修饰的载体包装并递送至HIV感染的细胞。 在更昔洛韦存在下，通过消除感染细胞抑制HIV复制。 然后利用瞬时tat RNA转染和GFP表达来选择修饰的细胞。 然后选择载体修饰的干细胞用于移植回患者体内，从而在患者不存在HIV tat的情况下修饰的载体保持休眠时在患者体内产生正常的免疫系统。

公开(公告)号：WO2020081759A1

公开(公告)日：2020-04-23

申请号：PCT/US2019/056645

申请日：2019-10-17

Applicant: TEXAS TECH UNIVERSITY SYSTEM

Inventor： GARG, Himanshu ,  JOSHI, Anjali

IPC: A61K39/12 ,  C07K14/005 ,  C07K14/18 ,  C07K19/00 ,  C12N5/10 ,  C12N7/00

Abstract: The present invention includes composition and methods for making multivalent vaccines for immunization against flavivirus and/or arboviruses including a multivalent Virus Like Particles (VLP) and mixtures thereof, the method comprising: method of making a flavivirus and/or arboviruses Virus Like Particles (VLP) comprising: inserting two or more nucleic acids that encode at least one flavivirus protein into a lentiviral backbone vector; generating a lentivirus by transfecting a first cell line with the lentiviral backbone vector and isolating the lentivirus therefrom; transducing a second cell line with the lentivirus; culturing the transduced cell line under conditions in which the multivalent flavivirus Virus Like Particles (VLP) are released from the cell line; and isolating the flavivirus Virus Like Particles (VLP) from a culture supernatant, wherein a cell line makes a virus-specific VLP, and the VLPs are purified and then mixed in different combinations to make the multivalent vaccine.

公开(公告)号：WO2018237039A1

公开(公告)日：2018-12-27

申请号：PCT/US2018/038551

申请日：2018-06-20

Applicant: TEXAS TECH UNIVERSITY SYSTEM

Inventor： GARG, Himanshu ,  JOSHI, Anjali

IPC: C12N15/86 ,  A61K39/12

Abstract: The present invention includes compositions, methods, vectors, vaccines, cell lines and other constructs for making and used Zika virus Reporter Virus Particles (RVPs) and/or Virus Like Particles (VLPs) that are safe for handling and manufacturing and are able to generate an effective immune response against Zika virus and can be readily scaled up for cost-effective production.

公开(公告)号：WO2018200580A1

公开(公告)日：2018-11-01

申请号：PCT/US2018/029213

申请日：2018-04-24

Applicant: TEXAS TECH UNIVERSITY SYSTEM ,  GARG, Himanshu ,  JOSHI, Anjali

Inventor： GARG, Himanshu ,  JOSHI, Anjali

IPC: C07K14/73 ,  C07K16/28 ,  G01N33/543 ,  G01N33/563 ,  C12N15/867 ,  C12N15/86 ,  C12N5/071 ,  A61K48/00

Abstract: Aa gene therapy method comprises modifying at least one CD4 molecule to form CD4mod, marking target cells with immunomagnetic beads, and killing the marked target cells. The method comprises applying a first vector that expressesTK-SR39 and applying a second vector that expresses HIV Tat and a CRISPR-CCR5 cassette to knockout CCR5. TheTK- SR39 rapidly kills cells in a presence of Ganciclovir.